Haoxi Health Launches $7.5M Direct Share Offering, 20% Dilution Impact
HAO•Haoxi Health Technology launched a registered direct offering of 5 million American Depositary Shares at $1.50 each, securing $7.5 million in gross proceeds. The deal includes warrants exercisable at $2.00 per ADS for five years, potentially diluting existing holders by 20% and extending cash runway into early 2027.
1. Direct Offering Details
Haoxi Health filed a prospectus to sell 5 million American Depositary Shares at $1.50 each in a registered direct offering, aiming to raise $7.5 million before expenses. The financing includes accompanying five-year warrants to purchase up to 5 million ADSs at $2.00 per share.
2. Shareholder Dilution Impact
Assuming full exercise of the warrants, existing ADS holders face dilution of approximately 20%. Management acknowledges the short-term share pressure but emphasizes the necessity of bolstering the balance sheet.
3. Use of Proceeds and Runway Extension
Net proceeds are earmarked for clinical development, working capital and general corporate purposes. The company expects the funding to extend its cash runway into the first quarter of 2027, supporting product pipeline advancement.
